Pharmacodynamic Response Assessment With PET/MRI Imaging in Patients With Metastatic Prostate CAncer to Bone Treated With ZD4054.
Phase of Trial: Phase II
Latest Information Update: 26 Apr 2013
At a glance
- Drugs Zibotentan (Primary)
- Indications Bone metastases; Prostate cancer
- Focus Therapeutic Use
- 26 Apr 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 30 Nov 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Nov 2011 Planned end date changed from 1 Apr 2011 to 1 Nov 2011 as reported by ClinicalTrials.gov.